Letter to the EditorFull Access
Published Online:1 Jan 2003https://doi.org/10.1176/appi.ajp.160.1.183-a
- Cited by
- Clinical Neuropharmacology, Vol. 37, No. 6
- Journal of Clinical Psychopharmacology, Vol. 29, No. 5
- 26 June 2016 | Australian & New Zealand Journal of Psychiatry, Vol. 41, No. 12
- 26 June 2016 | Australian & New Zealand Journal of Psychiatry, Vol. 40, No. 8
- SERGEY RASKIN,
M.D. , - ALEXANDER TEITELBAUM,
M.D. , - JOSEF ZISLIN,
M.D. , and - RIMONA DURST,
M.D. ,
1 January 2006 | American Journal of Psychiatry, Vol. 163, No. 1- SERGEY RASKIN,
- NADIA FETH,
M.D. , - KATJA CATTAPAN-LUDEWIG,
M.D. , , and - EVELINE JAQUENOUD SIROT,
M.SC. ,
1 January 2006 | American Journal of Psychiatry, Vol. 163, No. 1- NADIA FETH,
- JENNIFER L. ZACHER,
Pharm.D. , , and - A. DANIEL HATCHETT,
M.D. ,
1 January 2006 | American Journal of Psychiatry, Vol. 163, No. 1- JENNIFER L. ZACHER,
- 1 January 2003 | Pharmacoepidemiology and Drug Safety, Vol. 12, No. 5